News & Resources

WALTHAM, MA—August 10, 2021 — CorEvitas, LLC, the leading sponsor of registries in autoimmune and inflammatory diseases announces first patient enrollment in a new biospecimen study for patients enrolled in its rheumatology registries. Eligible rheumatology registry patients will contribute biological specimens that will be linked to longitudinal provider reported clinical and patient reported outcomes.

“We are excited to launch this biospecimen study to help advance the development of personalized therapies and diagnostics for rheumatology patients. We envision that this biospecimen study will enable us to uncover even deeper clinical insights from patients in order to improve care,” said Austin Read, Vice President, Biospecimen Solutions.

CorEvitas previously conducted the largest and most comprehensive clinical study comparing the effectiveness of patients starting or switching biologic agents for rheumatoid arthritis in the CERTAIN [Comparative Effectiveness Registry to Study Therapeutics for Arthritis and Inflammatory Conditions] study. Through CERTAIN, over 80,000 longitudinal samples were collected from 2200 patients. The impact of the data captured and analyzed was significant, contributing to over 12 manuscripts to date, including studies of biomarkers to predict response to anti-TNF biologics.

The recently launched Rheumatology Precision Medicine Initiative will be used for various purposes, including to support the identification and validation of biomarkers predictive of drug toxicities, safety outcomes, and clinical response to specific therapies used for rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis conditions. Other objectives include research on biomarkers that describe disease activity or phenotypic disease subsets, and research to understand mechanisms of disease and comorbidities. Generated molecular data will provide a holistic snapshot of rheumatology patients by complementing the already available clinical and patient experiential data.

“We are incredibly appreciative to have such highly committed rheumatology investigators who have collaborated with CorEvitas for the CERTAIN study, capturing not only robust longitudinal clinical data on real-world effectiveness, but also an array of peripheral blood biospecimens. With our new JAK inhibitor precision medicine study, we anticipate advancing our understanding to predict which patients will be more likely to respond to JAK inhibitors,” said Dr. Jeff Greenberg, Chief Medical Officer of CorEvitas.

CorEvitas will seek to enroll a minimum of 3,000 patients, leveraging its rheumatology network of over 85 sites. To learn more about this study and CorEvitas’ biospecimen capabilities, visit www.corevitas.com/contact-us.

About CorEvitas^SM

CorEvitas is the built for purpose gold-standard provider of real-world evidence. Through syndicated registry data and analytic services, CorEvitas helps biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators. CorEvitas operates nine major autoimmune registries across the US, Canada, and Japan, collecting data from over 500 participating investigator sites. In addition to supporting hundreds of manuscripts and abstracts, CorEvitas has supported post approval safety commitments for multiple newly approved treatments in autoimmune diseases for both U.S. and European regulators. CorEvitas is headquartered in Waltham, MA. Its patient experience division, HealthiVibe, complements and strengthens the company’s strong presence in disease registries by providing market-leading expertise in supporting innovative, evidence-based patient engagement initiatives across the product lifecycle. CorEvitas’ HealthUnlocked technology platform hosts over 1.4M patients in hundreds of condition-specific communities and significantly expands the scope of patient experiential data. Through Health iQ, CorEvitas has access to a broad range of UK and international data sets across primary and secondary care, as well as deep relationships with the NHS and leading UK academic institutions. Vestrum Health, a leader in data analytics of retinal practice Electronic Health Records, provides insightful views of retinal diseases across the drug life cycle. CorEvitas is a portfolio company of Audax Private Equity.

Insights advance clinical development, inform trial design and recruitment, substantiate value narratives, and inform patient-specific intervention plans

Waltham, MA, September 21, 2021—CorEvitas, LLC, the gold-standard leader in longitudinal real-world data in autoimmune and inflammatory diseases, today announced that it has expanded its engagement with Inovalon’s (NASDAQ:INOV) life sciences business unit specializing in data-driven healthcare analytics and strategic advisory services, to provide a holistic view of patients with rheumatoid arthritis or psoriasis.

In conjunction with CorEvitas’ granular clinical data on validated physician assessments and patient-reported outcomes, this collaboration focuses on rheumatoid arthritis and psoriasis and highlights one of many critical chronic condition-focused use cases of Inovalon’s MORE2 Registry® dataset, which today provides the healthcare marketplace insight into tens millions of patients suffering from key chronic conditions that contribute to poor clinical outcomes and increased healthcare costs in the United States.

“The healthcare marketplace, especially life sciences companies and health plans, have been eager to make more definitive connections between clinical measures, patient adherence, laboratory values, healthcare resource utilization, and economic outcomes along the patient journey,” said John E. Linnehan, practice director of Inovalon’s health economics and advanced analytics team. “We are excited to collaborate with CorEvitas to accelerate these insights with an initial focus on rheumatoid arthritis and psoriasis.”

With a comprehensive snapshot of individual patients with either rheumatoid arthritis or psoriasis, unique from any one given dataset, CorEvitas’ experts are presented with the opportunity for real-world and longitudinal assessment of the dynamics between demographics, clinical characteristics, functional status, patient-reported outcome measures, laboratory values, healthcare resource utilization, and economic outcomes. Insights made possible through these analytics can advance clinical development, inform trial design and recruitment, substantiate value narratives, and inform patient-specific intervention plans.

Raymond Hill, Chairman and Chief Executive Officer for CorEvitas, noted, “As an organization, we recognize the immeasurable value of understanding the whole patient. By furthering our collaboration with Inovalon, we can leverage the data-driven insights that provide integrated and actionable insights for the patient. This symbiotic expansion of real-world evidence will ultimately advance healthcare to its next level.”

CorEvitas collects comprehensive, prospective and structured gold-standard data that provides unmatched clinical depth and granularity. Data collected from over 475 sites in the U.S., Canada, and Japan make CorEvitas the largest network of real-world investigators contributing prospective data for patients with autoimmune and inflammatory conditions.

“We are excited to be able to provide our subscriber base with these expanded use cases,” said Leslie Harrold, MD, MPH, Chief Scientific Officer of CorEvitas. “So much real-world data is siloed. By connecting data, we can understand so much more about our patients and their needs – ultimately improving care paradigms.”

About CorEvitas

CorEvitas is the built-for-purpose gold-standard provider of real-world evidence. Through syndicated registry data and analytic services, CorEvitas helps biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators. CorEvitas operates eight major autoimmune and inflammatory registries across the U.S., Canada, and Japan, collecting data from nearly 500 participating investigator sites. In addition to supporting hundreds of manuscripts and abstracts, CorEvitas has supported post approval safety commitments for multiple newly approved treatments in autoimmune diseases for both U.S. and European regulators. CorEvitas is headquartered in Waltham, MA. Its subsidiary, HealthiVibe, complements and strengthens the company’s strong presence in disease registries by providing market-leading expertise in supporting innovative, evidence-based patient engagement initiatives across the product lifecycle. The HealthUnlocked technology platform hosts over 1.4 million patients in hundreds of condition-specific communities and significantly expands the scope of patient experiential data. Through Health iQ, CorEvitas has access to a broad range of UK and international datasets across primary and secondary care, as well as deep relationships with the NHS and leading UK academic institutions. Vestrum Health, a leader in data analytics of retinal practice Electronic Health Records, provides insightful views of retinal diseases across the drug life cycle. CorEvitas is a portfolio company of Audax Private Equity.

About Inovalon

Inovalon is a leading provider of cloud-based platforms empowering data-driven healthcare. Through the Inovalon ONE® Platform, Inovalon brings to the marketplace a national-scale capability to interconnect with the healthcare ecosystem, aggregate and analyze data in real time, and empower the application of resulting insights to drive meaningful impact at the point of care. Leveraging its Platform, unparalleled proprietary datasets, and industry-leading subject matter expertise, Inovalon enables better care, efficiency, and financial performance across the healthcare ecosystem. From health plans and provider organizations, to pharmaceutical, medical device, and diagnostics companies, Inovalon’s unique achievement of value is delivered through the effective progression of “Turning Data into Insight, and Insight into Action®.” Supporting thousands of customers, including all 25 of the top 25 U.S. health plans, all 25 of the top 25 global pharma companies, 24 of the top 25 U.S. healthcare provider systems, and many of the leading pharmacy organizations, device manufacturers, and other healthcare industry constituents, Inovalon’s technology platforms and analytics are informed by data pertaining to more than one million physicians, 584,000 clinical facilities, 338 million Americans, and 63 billion medical events. For more information, visit www.inovalon.com.

Waltham, MA and London, UK, August 3, 2021—CorEvitas, LLC welcomes Amrit Ray, MD, MBA, to its Board of Directors. CorEvitas [kohr-eh’-vi-tahs] is the built-for-purpose provider of gold-standard real-world evidence, striving to advance patient care by generating high quality curated data on newly approved therapies.

“I am honored to join the Board of Directors of CorEvitas. With a 20-year track record of excellence in real-world evidence, CorEvitas is a visionary organization. I have dedicated my professional career to advancing medical breakthroughs and championing healthcare access for patients, and CorEvitas is fundamentally driven by the same motivation. Drawing on specialty data sets, a unique understanding of regulatory needs, and unparalleled standards for data analytics, CorEvitas is driving forward the field of real-world evidence. I look forward to partnering with the Board and management team to help advance the company’s mission: to uncover deep clinical insights that lead to safer, more effective treatments and better patient care,” notes Dr. Ray.

Dr. Ray brings a wealth of expertise in biopharmaceutical R&D as a highly accomplished industry leader with three decades of healthcare experience. He currently serves as a Senior Advisor to Bain Capital Life Sciences, which invests in biopharma, medical device, diagnostics, and technology companies that drive medical innovation. Previously, Dr. Ray was Global President, R&D and Medical, and Executive Leadership Team member at Pfizer Upjohn, overseeing all Phase I-IV research and development, regulatory, safety and medical affairs for the organization. Prior to Pfizer, Dr. Ray served as Chief Medical Officer and R&D Leadership Team Member for pharmaceuticals at Johnson & Johnson.

“CorEvitas continues to evolve as a global leader in real-world evidence. The future of this landscape includes a deeper, more holistic view of the patient and leverages real-world evidence to substantiate the health and safety of patients. Amrit’s experience, building patient focus and healthcare access while propelling forward research and innovation will be pivotal to our growth as an organization,” said Raymond Hill, CEO and Chairman of CorEvitas.

CorEvitas continues to build a leading position in real-world evidence across registries, patient experience, electronic health records, claims and data analytics, as well as precision medicine and biorepository solutions.

Providing curated data while leveraging a cloud-based secure technology platform enables the company to aggregate and process longitudinal data at scale and handle a broad spectrum of clinical and patient-reported outcomes. The organization is committed to ensuring the best therapies and care are delivered to the patients that need them the most.

Joe Rogers, Managing Director at Audax Private Equity, shares, “Dr. Ray is a renowned and experienced executive with a record of driving positive impact for patients and advancements for our healthcare system. His deep functional experience across R&D, medical affairs, and real-world evidence has contributed to advancing pipeline development while optimizing patient impact across multiple therapeutic areas including oncology, immunology, and neuroscience to name a few. We anticipate his guidance and leadership in this space to have a significant impact on CorEvitas’ corporate strategy and growth trajectory.”

About Audax Private Equity

Audax Group is a leading alternative investment manager with offices in Boston, New York, and San Francisco. Since its founding in 1999, the firm has raised over $30 billion in capital across its Private Equity and Private Debt businesses. Audax Private Equity has invested over $7 billion in more than 140 platforms and over 975 add-on companies, and is currently investing out of its $3.5 billion, sixth private equity fund. Through its disciplined Buy & Build approach, Audax Private Equity seeks to help platform companies execute add-on acquisitions that fuel revenue growth, optimize operations, and significantly increase equity value. With more than 250 employees, Audax is a leading capital partner for North American middle market companies. For more information, visit the Audax Private Equity website: www.audaxprivateequity.com or follow us on LinkedIn.
About CorEvitas

CorEvitas is the built-for-purpose gold-standard provider of real-world evidence. Through syndicated registry data and analytic services, CorEvitas supports biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators. CorEvitas operates eight major autoimmune and inflammatory registries across the US, Canada, and Japan, collecting data from almost 500 participating investigator sites. In addition to supporting hundreds of manuscripts and abstracts, CorEvitas has supported post approval safety commitments for multiple newly approved treatments in autoimmune diseases for both U.S. and European regulators. CorEvitas is headquartered in Waltham, MA. HealthiVibe, a subsidiary of CorEvitas, complements and strengthens the company’s strong presence in disease registries by providing market-leading expertise in supporting innovative, evidence-based patient engagement initiatives across the product lifecycle. The HealthUnlocked technology platform hosts over 1.4M patients in hundreds of condition-specific communities and significantly expands the scope of patient experiential data. Through Health iQ, CorEvitas has access to a broad range of UK and international data sets across primary and secondary care, as well as deep relationships with the NHS and leading UK academic institutions. Vestrum Health a leader in data analytics of retinal practice Electronic Health Records provides insightful views of retinal diseases across the drug life cycle. CorEvitas is a portfolio company of Audax Private Equity.

Retina specialty data provider combines with leader in real-world evidence

Waltham, MA, USA, London, UK, and Naperville, IL, USA, July 22, 2021—CorEvitas, LLC is pleased to share the addition of Vestrum Health to its organization.

Vestrum Health, the first-to-market leader in data analytics of retina electronic health record (EHR) data, empowers retina practices to optimize clinical performance and patient outcomes by leveraging real-world clinical applications. Vestrum Health’s data provide insightful views across the drug life cycle to biopharmaceutical companies focused on retinal diseases.

Tom Brogan, CEO of Vestrum Health, notes, “We are excited to join CorEvitas. By joining forces, Vestrum will be better positioned to expand its capabilities in retinal diseases, improving patient care and supporting our practices with deeper clinical insights. This expansion will broaden our scope and ability to provide real-world clinical data to support all phases of clinical research and commercialization.”

CorEvitas, a leading provider of highly curated registry data in autoimmune and inflammatory diseases continues to build a prominent, global real-world evidence organization. With the addition of Vestrum Health, CorEvitas expands its EHR data capabilities—providing expanded opportunities for real-world evidence generation leveraging specialty data for retinal diseases.

Jilani Gulam, President, CorEvitas Europe shared, “Since its founding, CorEvitas has been committed to improving the lives of patients, by systematically collecting high quality data and applying rigorous analytical methods. Like CorEvitas, Vestrum has been focused on building high quality specialty data sets. CorEvitas’ expansion and new capabilities continue to accelerate the achievement of its mission with innovative high quality curated data sources in new diseases.”

CorEvitas provides a holistic approach to capturing real-world data through patient-centered solutions including clinical registries, patient insight studies, biospecimen solutions and specialty EHR data. Providing curated data while leveraging a cloud-based secure technology platform enables the company to aggregate and process longitudinal data at scale and handle a broad spectrum of clinical and patient-reported outcomes.

Both organizations have built extensive networks of specialty physicians and practices. Vestrum Health currently partners with about 300 retinal physicians across the U.S. and the CorEvitas network collects comprehensive registry data from almost 500 sites in the U.S., Canada, and Japan. The level of transparency and trust in capturing high quality patient data while maintaining advanced standards of confidentiality and privacy is unparalleled in both organizations and will continue to be a primary focus moving forward.

Vestrum Health will continue serving the industry and its practices within the CorEvitas corporate family. There will be no change in the relationships with industry or partner practices.

Notes David Williams, MD, co-founder of Vestrum Health and past President of the American Society of Retinal Surgeons (ASRS), “Vestrum was founded on the principles of advancing patient care and bringing value to physicians and practices from their Electronic Health Record investments. The combination with CorEvitas fits perfectly with these principles, vastly enhancing the capabilities of both companies.”

John Pollack, MD, co-founder of Vestrum Health and past President of the ASRS adds “We are looking forward to leveraging CorEvitas’ breadth and depth of expertise in medical registry development and analytics to allow Vestrum to rapidly expand its range of services. The publication track records of both companies demonstrates our common commitment to improving patient care and the introduction of new Vestrum services will lead to continued gains in the value of practices’ EHR systems.”

About Vestrum Health

Vestrum Health was founded in 2012 to provide physicians with the opportunity to unlock the value of their EHR data. The company’s innovative and proprietary technology platform facilitates the aggregation and de-identification of EHR data for clinical research, analytics, and commercialization. Vestrum maintains close contact with practices in providing valuable insights into trends in outcomes, workflow measures and other metrics used by practices to improve patient care. Vestrum Health has supported clinical researchers both in private practice and industry in the development of numerous academic papers. The company provides assistance to practices in conducting analysis of patients who may be suitable for clinical trials and who meet criteria specified by the practice. Vestrum provides industry with key trends, clinical outcomes in a real-world setting, treatment patterns, use of technology and an extensive number of other analysis provided through syndicated reports and custom analytics.

About CorEvitasSM

CorEvitas is the built-for-purpose gold-standard provider of real-world evidence. Through syndicated registry data and analytic services, CorEvitas helps biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators. CorEvitas operates eight major autoimmune and inflammatory registries across the US, Canada, and Japan, collecting data from over 475 participating investigator sites. In addition to supporting hundreds of manuscripts and abstracts, CorEvitas has supported post approval safety commitments for multiple newly approved treatments in autoimmune diseases for both U.S. and European regulators. CorEvitas is headquartered in Waltham, MA. HealthiVibe, a division of CorEvitas, complements and strengthens the company’s strong presence in disease registries by providing market-leading expertise in supporting innovative, evidence-based patient engagement initiatives across the product lifecycle. The HealthUnlocked technology platform hosts over 1.4 million patients in hundreds of condition-specific communities and significantly expands the scope of patient experiential data. Through HealthiQ, CorEvitas has access to a broad range of UK and international data sets across primary and secondary care, as well as deep relationships with the NHS and leading UK academic institutions. CorEvitas is a portfolio company of Audax Private Equity.